Loading…
Loading…
MTSR (Metsera, Inc.) is no longer actively trading.
This usually means the company was acquired and taken private, delisted from its exchange, or its ticker has been retired. Every price, valuation, dividend, and analyst figure on this page is frozen at the last available trading session and reads as historical reference — not a current-day signal.
MTSR does not currently pay a dividend.
Sell-side consensus EPS, revenue estimates, YoY growth, forward P/E, and per-year analyst coverage — for any covered stock.
Click below to see what's inside, then upgrade to unlock for this and 80,000+ other tickers.
See price against where its own fundamentals say it should trade — the shaded gap is the discount or premium, across five valuation lenses.
Click below to see what's inside, then upgrade to unlock for MTSR and 80,000+ other tickers.
See exactly how MTSR's revenue becomes profit — a Sankey that traces revenue (and its reported segments) through gross profit, operating expenses, and net profit, with the year-over-year change on every line.
The same diagram the Chart Builder draws, right on the Summary tab. Upgrade to unlock it for MTSR and 80,000+ other tickers.
Metsera, Inc. operates as a clinical-stage biotechnology firm, specializing in crafting both injectable and oral nutrient-stimulated hormone analog peptides. These therapeutic compounds are primarily aimed at addressing obesity, overweight conditions, and associated health issues. Its developmental pipeline features MET-097i and MET-233i, both under investigation for treating obesity and overweight patients. Furthermore, Metsera is advancing a potential combination therapy involving MET-233i and MET-097i. The company is also progressing additional drug candidates, including MET-002, MET-224o…
Railpen has raised its takeover proposal for IP Group PLC (LSE:IPO), offering shareholders a mix of cash, shares in Oxford Nanopore and a contingent payout linked to the biotech firm Metsera. The pension fund manager, IP Group's largest shareholder with an 18.4% stake, has made two improved proposals to the board since its initial approach on 22 June, following meetings with shareholders and directors.
Shares in IP Group PLC (LSE:IPO) rose 9% to 53.5p on Monday after the company reported net asset value per share climbing to 110.4p, with total NAV reaching £975.1 million. The recovery was driven largely by Pfizer's acquisition of Metsera, a biotechnology company developing obesity treatments.
Metsera Inc. (NASDAQ: MTSR - Get Free Report) has been given a consensus rating of "Hold" by the eight analysts that are presently covering the firm, Marketbeat Ratings reports. One investment analyst has rated the stock with a sell rating, three have issued a hold rating and four have issued a buy rating on the company.
NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) today announced the successful completion of its acquisition of Metsera, Inc. (NASDAQ: MTSR), a clinical-stage biopharmaceutical company accelerating the next generation of medicines for obesity and cardiometabolic diseases. “This strategic milestone represents more than a transaction—it's a deliberate investment in the future of medicine. By acquiring Metsera, we are directing our resources toward one of the most impactful and high-growth ther.
Metsera shareholders on Thursday approved Pfizer's takeover offer worth up to $10 billion, allowing the U.S. pharmaceutical giant re-entry into the lucrative obesity treatment market after a fierce bidding war with Wegovy-maker Novo Nordisk.